
The Malaria Vaccine (MalVax) Alliance
Accelerating the development of better vaccines for a malaria free future
INTRODUCING MALVAX
The Malaria Vaccine (MalVax) Alliance is a new global, independent collaboration accelerating the development of malaria vaccines.
The MalVax Alliance unites the malaria vaccine R&D community to drive evidence and innovation from lab to policy faster, so better vaccines reach the people who need them sooner. It coordinates action around shared priorities by:
Strengthening innovation and clinical investigation through shared frameworks
Improving the quality and comparability of research evidence
Accelerating the translation of that evidence into regulatory and policy decisions
MalVax 2027: The First Global Malaria Vaccine Alliance R&D Conference
THE OPPORTUNITY
Global coordination will accelerate impactful malaria vaccine development
Recent consultations across the malaria vaccine community have highlighted opportunities to address persistent challenges slowing the development of improved next-generation malaria vaccines. The areas identified include increasing coordination, harmonising clinical trial designs, supporting and improving data comparability, and supporting increased clarity and evidence for funding, policy, regulatory and implementation pathways.
Stakeholders agreed that an impartial and objective mechanism could help improve community coordination and alignment, accelerate and facilitate decision-making during product development, and help guide and accelerate the next phase of next-generation malaria vaccine innovation.
The MalVax Alliance was established in early 2026 in response to this call.The MalVax Alliance serves as an independent, global platform, uniting researchers, vaccine developers,funders, policymakers, regulators, and partners to working in malaria-endemic countries and internationally accelerate the development of effective, accessible, and affordable malaria vaccines.
Together, we are working to:

Share Science
Strengthen scientific exchange and shared knowledge across the community.

Break Bottlenecks
Coordinate expertise to address common research and development challenges.

Align Efforts
Improve comparability and support evidence generation across the ecosystem.
COMMITTEE
Executive Committee
The Executive Committee, assisted by a Support Unit at Bridges to Development, leads the work to build the foundations of an inclusive and effective MalVax Alliance:

Melissa Penny
Professor Fiona Stanley Chair in Child Health Research, The Kids Research Institute Australia, University of Western Australia (Australia)

Simon Draper
Professor of Vaccinology and Translational Medicine, University of Oxford (UK)

Katharine Collins
Senior Program Officer, Global Health R&D, Coefficient Giving (UK)
COMMITTEE
Advisory Group
The Advisory Group is composed of leaders drawn from across the malaria vaccine R&D community and related ecosystem. It provides strategic input and guidance to the Executive Committee, supporting early priority setting and governance design. This is an interim arrangement, in place until a permanent governance structure launches in 2027.

Peter Crompton
Senior Investigator, Malaria Infection Biology and Immunity Section, NIAID/DIR (USA)

Melissa Kapulu
Professor, Malaria Transmission & Human Infection Studies, KEMRI-Wellcome Trust Research Programme (Kenya)

Miriam K. Laufer
Global Clinical Franchise Leader, Sanofi (USA)

Abdisalan M. Noor
Executive Director, AHADI - Applied Health Analytics for Delivery and Innovation

Halidou Tinto
Director of Research in Parasitology, IRSS – Clinical Research Unit of Nanoro (Burkina Faso)

Nicola Viebig
Director of Research, European Vaccine Initiative (Germany)

Philip Welkhoff
Director, Malaria Program, Gates Foundation (USA)

Brandon Wilder
Associate Professor, Oregon Health & Science University (USA)

Lindsey Wu
Technical Officer, Malaria Vaccines, WHO (Switzerland)
WORKING GROUPS
MalVax Technical Working Groups
The Alliance's activities will be delivered initially through three Technical Working Groups:
WHO Technical Advisory Group (TAG) on malaria vaccines. Coming Soon.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod.
MalVax 2027: The First Global Malaria Vaccine Alliance R&D Conference
The First Global Malaria Vaccine (MalVax) Alliance R&D Conference will take place in Kuala Lumpur, Malaysia from 31 January to 3 February 2027, bringing together the international research and development (R&D) community to share evidence, strengthen collaboration, and accelerate progress towards next-generation malaria vaccines. It will also serve as a platform to share and collaborate on the newly launched MalVax Alliance Working Groups on clinical trial design and endpoints, assays, and modelling and share status of expected outputs.
CONFERENCE COMMITTEE
Scientific Conference Committee
With expertise spanning across the malaria vaccine R&D community, the MalVax Scientific Conference Committee (SCC) guides the scientific planning, abstract selection and delivery of this meeting. MalVax 2027 SCC members are:







REGISTRATION
Registration is now open!
Registration includes:
- All Conference Sessions
- Conference Catering (morning tea, lunch and afternoon tea)
- Welcome and Evening Receptions
Low- and middle income country (LMIC) rate
Standard rate
CALL FOR ABSTRACTS
Abstract submissions are now open!
Researchers of all career stages and partners from across the malaria vaccine R&D community are invited to submit their latest scientific work, including original research, new data, and innovations supporting the acceleration of malaria vaccine development.
Submission Requirements
Abstracts must be written in clear scientific English and should not exceed 275 words. Full details will be available on the submission portal.
Plasmodium falciparum vaccines will be the primary focus of the meeting, but abstracts covering Plasmodium vivax or multi-Plasmodium species vaccines, vaccines targeting malaria in pregnancy, or monoclonal antibodies are also welcomed for submission and consideration by the Scientific Conference Committee (SCC).
Timeline
PROGRAMME
Shaped by the science submitted to this conference
Our Programme will be shaped by the science abstracts submitted to this conference: aiming to represent all voices. The programme runs over three and a half days:
Meet in Malaysia
TRAVEL & VENUE
Planning your trip
The conference will take place in Kuala Lumpur, 31 January to 3 February 2027.
The conference was originally planned to be held in Kigali, Rwanda. In light of the evolving Ebola outbreak in the region, the organisers completed a review of alternative venues across Africa, Europe, and Asia. The review prioritised ease of participation for colleagues from Africa and other countries where visa access has historically been a barrier, together with cancellation risk, flight connectivity from all regions, and suitable meeting infrastructure.
Kuala Lumpur offers visa-free entry or straightforward online eVisas for most participants, strong flight connectivity avoiding Middle East transit hubs, and world-class meeting infrastructure. Travel and accommodation support will be available to encourage broad participation from colleagues in low- and middle-income countries, with further details shared at registration. As the meeting will not be virtual, selected abstracts will require in person attendance.

Planning ahead ensures a smoother journey. Review the latest requirements before booking your travel.
We anticipate that visas to travel to Malaysia will be straightforward. Nonetheless, all conference delegates are responsible for ensuring they meet Malaysia's entry requirements before travelling. Participants are encouraged to confirm the requirements applicable to their nationality before making travel arrangements. Please note that conference organisers will provide a letter of conference registration confirmation to support visa applications.

Malaysia eVISA Portal
Visa Requirements by Country


TRAVEL SUPPORT
Travel Support Application
MalVax 2027 registrants from low- and middle-income countries (LMICs) who require financial support to attend may apply for travel support. Please note that a limited number of grants is available.
The financial support is intended to offset travel costs associated with attending the conference, so finances are not a barrier to participation.
FUNDER
Coefficient Giving
The establishment of the MalVax Alliance and the initiation of the inaugural conference has been made possible thanks to support from Coefficient Giving.
Sponsorship interest
Organisations interested in sponsoring the conference are encouraged to reach out to the MalVax Support Unit at Bridges to Development:
STAY CONNECTED
Stay Informed about MalVax
If you have not done so yet, please sign up via our short engagment survey using the link below
For questions about MalVax or the inaugural conference, please contact the Support Unit at Bridges to Development
Social Media
We encourage interested partners to follow and use the hashtag #MalVax2027 on social media.